![Kathryn Haviland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Haviland
Président chez
FULCRUM THERAPEUTICS, INC.
Fortune : 161 755 $ au 31/05/2026
Profil
Kathryn Haviland est membre du conseil d'administration de Fulcrum Therapeutics, Inc. et directrice de l'exploitation de Blueprint Medicines Corp, membre de la Harvard Business School Health Industry Alumni Association et membre du Biopharma Executive Council. Mme Haviland a précédemment occupé le poste de vice-présidente des maladies rares chez Idera Pharmaceuticals, Inc, de chef du développement commercial chez Sarepta Therapeutics, Inc et de directrice exécutive du développement commercial chez PTC Therapeutics, Inc. Elle a obtenu un diplôme de premier cycle de l'université de Wesleyan et un MBA de la Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BICARA THERAPEUTICS INC. 0,01 % | 09/06/2026 | 7 437 ( 0,01 % ) | 161 755 $ | 31/05/2026 |
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 | |
AVALYN PHARMA INC -.--% | 30/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Kathryn Haviland
| Sociétés | Poste | Début |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Président | 10/01/2022 |
| BICARA THERAPEUTICS INC. | Directeur/Membre du Conseil | 21/09/2023 |
| AVALYN PHARMA INC. | Directeur/Membre du Conseil | 01/03/2026 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Corporate Officer/Principal | - |
Anciens postes connus de Kathryn Haviland
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Directeur Général | 01/01/2026 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 01/12/2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2012 |
Formation de Kathryn Haviland
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
74
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Commercial Services |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
